Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
EPRX Stock Chart & Stats
$5.96
-$0.02(-0.66%)
At close: 4:00 PM EST
$5.96
-$0.02(-0.66%)
Day’s Range― - ―
52-Week Range$2.68 - $7.19
Previous CloseN/A
Volume2.60K
Average Volume (3M)148.90K
Market Cap
C$280.96M
Enterprise Value$295.74M
Total Cash (Recent Filing)C$123.78M
Total Debt (Recent Filing)C$237.38K
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 31, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding50,598,330
10 Day Avg. Volume43,828
30 Day Avg. Volume148,898
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.18
Price to Sales (P/S)0.00
P/FCF Ratio-3.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.66Price Target Upside95.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe EP-104GI advanced through key milestones during the quarter, with the highest dose evaluated to date confirming sustained symptom improvement and tissue response following a single administration.
Financial OutlookEupraxia Pharmaceuticals made significant advancements on its pipeline, and its overall spending remained disciplined, supporting the company's view of a cash runway into 2028.
Market PotentialThe durable twelve-month efficacy and validation of once-yearly dosing further expands the commercial potential of EP-104GI in a U.S. EoE market exceeding one million patients.
Bears Say
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $2.68 and its highest was $7.19 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$280.96M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 117 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.191 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.014.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.14.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 50,598,330 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.191 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went up 4.037%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$11.66 (95.70% Upside)
C$11.66 (95.70% Upside)
Insider Transactions
Bought Shares
Worth C$4.9M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.00%
12-Months-Change
Fundamentals
Return on Equity
-158.24%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Stock 12 Month Forecast
Average Price Target
$11.66
▲(95.70% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Fennec Pharmaceuticals
―
NervGen Pharma
―
Bright Minds Biosciences
―
Ownership Overview
17.62% Insiders
21.13% Other Institutional Investors
61.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---